Please assess the completion status of the following clinical trial:

Trial Title: Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents for Diffuse Long Coronary Artery Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 and more~* Diffuse long native coronary artery stenosis (\>50% by visual estimate) with lesion length of more than 40 mm requiring at least 2 overlapped stents with a reference-vessel diameter of 2.5 to 3.75 mm on visual assessment~* Patients with silent ischemia, stable or unstable angina pectoris, and acute myocardial infarction including NSTEMI or STEMI~* The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site~Exclusion Criteria:~* Subject has known hypersensitivity or contraindication to device material and its ingredients (everolimus, poly(L-lactide), poly(DL-lactide), lactide, lactic acid) and cobalt, chromium, nickel, platinum, tungsten, acrylic, and fluoro polymers that cannot be adequately premedicated~* Subject has known allergic reaction, hypersensitivity, or contraindication to aspirin; to clopidogrel and prasugrel and ticagrelor; or to heparin and therefore cannot be adequately treated with study medication~* An elective surgical procedure is planned that would necessitate interruption of antiplatelet drugs within 12 m after the procedure~* STEMI requiring primary percutaneous coronary intervention~* Cardiogenic shock~* Restenotic lesions~* Left main~* Extreme angulation (≥90°) or excessive tortuosity (≥two 45° angles) proximal to or within the target lesion~* Heavy calcification proximal to or within the target lesion~* Compromised left ventricular dysfunction (LVEF \<30%)~* At the time of screening, the subject has a malignancy that is not in remission~* Terminal illness with life expectancy \<1 year~* Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period~* Patient's pregnant or breast-feeding or child-bearing potential

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ABSORB BVS (Type: EXPERIMENTAL): None
- XIENCE EES (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).